Great to see the growth from the team and de-risking that happened over the year.
Start of 2021:
-1 asset
-1 clinical program
-1 disease area
-Share price: 36 cents
Today:
-7 assets
-8 clinical programs
-10 disease areas
-Share price: 21.5 cents
I think it is a bargain at these prices. Another example of the Aussie market not understanding biotechs, and the typical investor not having the patience for biotechs. DYOR
- Forums
- ASX - By Stock
- Chimeric: Media Thread
Great to see the growth from the team and de-risking that...
-
-
- There are more pages in this discussion • 667 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
CHM (ASX) Chart |
Day chart unavailable